; (iv) an analysis of the factors that result in determinations to qualify or not qualify a nonclinical testing method under this section; and (v) the number of applications received under section 505 of this Act or section 351 of the Public Health Service Act that rely on a nonclinical testing method qualified under this section, and the number of such applications approved; and (B) for the period beginning on the date of enactment of this section through the end of the period covered by the report, the number of animals estimated to have been saved as a result of the process under this section. (g) Nonclinical testing method defined In this section, the term nonclinical testing method has the meaning given to such term in section 505(z) except that such term excludes any animal test. . (b) Public meeting Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services shall publish in the Federal Register a notice to convene a public meeting to discuss and obtain input and recommendations from relevant stakeholders, including regulated industry, biomedical consortia, contract research organizations, and patients, regarding— (1) the goals and scope of the process under 507A of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a); (2) a framework, procedures, and requirements for such process; and (3) ways in which the Food and Drug Administration will support the use of nonclinical testing methods to replace or reduce the use of animals in nonclinical testing. (c) FDA guidance (1) Nonclinical testing methods qualification process The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall— (A) not later than 1 year after the date of the public meeting under subsection (b), propose guidance on the goals and implementation of the process under section 507A of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a); (B) provide a period for public comment on such proposed guidance